Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance.
In 100 untreated patients with chronic lymphocytic leukaemia (CLL) lymphocyte doubling time (LDT) has been investigated in relationship with clinical stages, bone marrow histological patterns, treatment-free period and survival. Although partially correlated with clinical stages and bone marrow patterns, LDT has a clear prognostic significance by itself: whereas a LDT of 12 or less months identifies a population of patients with poor prognosis, a LDT higher than 12 months is indicative of good prognosis as substantiated by a long treatment-free period and survival. This simple parameter can be useful in the clinical management of CLL patients.
D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000473:pathology; D002455:Cell Division; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000097:blood* / Q000401:mortality / Q000473:pathology; D007958:Leukocyte Count; D008214:Lymphocytes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies